AU2015237241B2 - L-2-hydroxyglutarate and stress induced metabolism - Google Patents

L-2-hydroxyglutarate and stress induced metabolism Download PDF

Info

Publication number
AU2015237241B2
AU2015237241B2 AU2015237241A AU2015237241A AU2015237241B2 AU 2015237241 B2 AU2015237241 B2 AU 2015237241B2 AU 2015237241 A AU2015237241 A AU 2015237241A AU 2015237241 A AU2015237241 A AU 2015237241A AU 2015237241 B2 AU2015237241 B2 AU 2015237241B2
Authority
AU
Australia
Prior art keywords
hypoxia
agent
level
tissue
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015237241A
Other languages
English (en)
Other versions
AU2015237241A1 (en
Inventor
Andrew M. INTLEKOFER
Craig B. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015237241A1 publication Critical patent/AU2015237241A1/en
Application granted granted Critical
Publication of AU2015237241B2 publication Critical patent/AU2015237241B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
AU2015237241A 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism Ceased AU2015237241B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972091P 2014-03-28 2014-03-28
US61/972,091 2014-03-28
PCT/US2015/023038 WO2015148950A1 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism

Publications (2)

Publication Number Publication Date
AU2015237241A1 AU2015237241A1 (en) 2016-10-20
AU2015237241B2 true AU2015237241B2 (en) 2021-07-29

Family

ID=54196451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015237241A Ceased AU2015237241B2 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism

Country Status (6)

Country Link
US (2) US10450596B2 (enExample)
EP (1) EP3122893B1 (enExample)
JP (2) JP6953305B2 (enExample)
AU (1) AU2015237241B2 (enExample)
CA (1) CA2943823C (enExample)
WO (1) WO2015148950A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012340192B2 (en) 2011-11-18 2016-04-07 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
CA3053356A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
JP6977999B2 (ja) * 2018-08-22 2021-12-08 国立大学法人京都大学 胚培養培地、及び胚培養方法
FR3097739B1 (fr) * 2019-06-25 2022-03-04 Lnc Therapeutics Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate
CN112830958B (zh) * 2021-02-05 2022-06-14 山东大学 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20060084123A1 (en) 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
AU2003302132B2 (en) * 2002-11-21 2008-02-21 Inverness Medical Switzerland Gmbh Bodily fluid markers of tissue hypoxia
US20090186358A1 (en) 2007-12-21 2009-07-23 Wyeth Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SE534542C2 (sv) 2009-09-30 2011-09-27 Calmark Sweden Ab Testsystem för bestämning av hypoxiutlöst cellskada
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20120202883A1 (en) 2011-01-20 2012-08-09 Duke University Effects of idh1 and idh2 mutations on the cellular metabolome
EP2788763A4 (en) * 2011-12-09 2015-10-07 Metabolon Inc BIOMARKERS FOR RENAL CANCER AND METHODS OF USE
US8977473B2 (en) 2012-08-29 2015-03-10 Caterpillar Inc. Pressure control strategy for dual fuel compression ignition engine and machine using same
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia

Also Published As

Publication number Publication date
EP3122893A1 (en) 2017-02-01
US20170175164A1 (en) 2017-06-22
CA2943823C (en) 2023-10-10
CA2943823A1 (en) 2015-10-01
US20200032315A1 (en) 2020-01-30
WO2015148950A1 (en) 2015-10-01
EP3122893A4 (en) 2017-12-13
JP7208323B2 (ja) 2023-01-18
EP3122893B1 (en) 2021-06-02
JP6953305B2 (ja) 2021-10-27
JP2017520774A (ja) 2017-07-27
JP2022008641A (ja) 2022-01-13
US10450596B2 (en) 2019-10-22
US11788112B2 (en) 2023-10-17
AU2015237241A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US11788112B2 (en) L-2-hydroxyglutarate and stress induced metabolism
Jiang et al. RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation
Lu et al. ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition
Gangat et al. JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management
Terunuma et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Wang et al. Ablation of LGR4 promotes energy expenditure by driving white-to-brown fat switch
Sun et al. LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer
Tang et al. Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma
Huang et al. SNAP25 inhibits glioma progression by regulating synapse plasticity via GLS-mediated Glutaminolysis
Antico Arciuch et al. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells
Guo et al. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4
He et al. A novel lncRNA MDHDH suppresses glioblastoma multiforme by acting as a scaffold for MDH2 and PSMA1 to regulate NAD+ metabolism and autophagy
Zhang et al. Aldehyde oxidase 1 promoted the occurrence and development of colorectal cancer by up-regulation of expression of CD133
Zhang et al. CBX7 suppression prevents ischemia-reperfusion injury-induced endoplasmic reticulum stress through the Nrf-2/HO-1 pathway
Salomone et al. SIRT5 rs12216101 T> G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease
Vo et al. Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment
López-Pérez et al. Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice
Yuan et al. miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2
Ling et al. Serotonylation in tumor-associated fibroblasts contributes to the tumor-promoting roles of serotonin in colorectal cancer
Guo et al. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer
Stefanowicz-Rutkowska et al. Is there a relationship between the prevalence of autoimmune thyroid disease and diabetic kidney disease?
Córdoba‐Jover et al. Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans
Sanchez-Roman et al. Two Cockayne Syndrome patients with a novel splice site mutation–clinical and metabolic analyses
Tang et al. Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis
Mai et al. Citraconate promotes the malignant progression of colorectal cancer by inhibiting ferroptosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired